SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| Ozevlor Plus | 80,25 mg,mg | Tablet · Oral use | 30 Blister | SAR 54.25 | Generic · Prescription | SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| Ozevlor Plus | 80,12.50 mg,mg | Tablet · Oral use | 30 Blister | SAR 54.25 | Generic · Prescription | SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| Ozevlor Plus | 40,12.50 mg,mg | Tablet · Oral use | 30 Blister | SAR 54.25 | Generic · Prescription | SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| MICARDIS PLUS | 40,12.5 mg,mg | Tablet · Oral use | 28 Blister | SAR 65.05 | NCE · Prescription | BOEHRINGER INGELHEIM | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
HYPERTENSION
US FDA United States — FDA approvals (Drugs@FDA)
EMA European Union — centrally authorised medicines
MicardisPlus Boehringer Ingelheim International GmbH · Authorised · authorised 19 Apr 2002 · ATC C09DA07
Therapeutic indication (EMA)
Treatment of essential hypertension. MicardisPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone. MicardisPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on MicardisPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Tolucombi Krka, d.d., Novo mesto · Authorised · authorised 13 Mar 2013 · ATC C09DA07
Therapeutic indication (EMA)
Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Actelsar HCT Actavis Group PTC ehf · Authorised · authorised 13 Mar 2013 · ATC C09DA07
Therapeutic indication (EMA)
Treatment of essential hypertension. Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone. Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone. Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Kinzalkomb Bayer AG · Withdrawn · authorised 19 Apr 2002 · ATC C09DA07
Therapeutic indication (EMA)
Treatment of essential hypertension. Kinzalkomb fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone. Kinzalkomb fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on Kinzalkomb (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
PritorPlus Bayer AG · Withdrawn · authorised 22 Apr 2002 · ATC C09DA07
Therapeutic indication (EMA)
Treatment of essential hypertension. PritorPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone. PritorPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on PritorPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | MICARDIS HCT 40-12.5 MG TABLET | $4.48356 | per EA | 23 Sep 2026 |
| US NADAC | MICARDIS HCT 80-12.5 MG TABLET | $4.472 | per EA | 23 Sep 2026 |
| US NADAC | MICARDIS HCT 80-25 MG TABLET | $4.4768 | per EA | 21 Jan 2026 |
| US NADAC | TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB | $0.3567 | per EA | 23 Sep 2026 |
| US NADAC | TELMISARTAN-HYDROCHLOROTHIAZIDE 80-12.5 MG TB | $0.31445 | per EA | 23 Sep 2026 |
| US NADAC | TELMISARTAN-HYDROCHLOROTHIAZIDE 80-25 MG TAB | $0.33828 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Telmisartan 40mg / Hydrochlorothiazide 12.5mg tablets | £2.63 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Telmisartan 80mg / Hydrochlorothiazide 12.5mg tablets | £4.22 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Telmisartan 80mg / Hydrochlorothiazide 25mg tablets | £17.00 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.3. Antihypertensive medicines · core
Essential hypertension
Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.